Enzymatica AB (SE:ENZY)

:ENZY

ENZY

Enzymatica AB

RESEARCH TOOLSreports

Want to see SE:ENZY full AI Analyst Report?

Enzymatica AB (ENZY) Price & Analysis

0 Followers

ENZY Stock Chart & Stats

kr2.00

-kr0.34(-10.43%)

At close: Mar 06 4:00 PM EST

kr2.00

-kr0.34(-10.43%)

Day’s Range― - ―

52-Week Rangekr1.60 - kr3.52

Previous CloseN/A

Volume634.97K

Average Volume (3M)93.66K

Market Cap

kr604.41M

Enterprise Valuekr579.02M

Total Cash (Recent Filing)kr26.06M

Total Debt (Recent Filing)kr661.00K

Price to Earnings (P/E)―

Beta0.23

Next Earnings

Jul 16, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.06

Shares Outstanding242,735,100

10 Day Avg. Volume44,136

30 Day Avg. Volume93,658

Financial Highlights & Ratios

PEG Ratio0.36

Price to Book (P/B)3.71

Price to Sales (P/S)8.56

P/FCF Ratio-11.19

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)-0.3

Revenue Forecast (FY)kr109.00M

Bulls Say, Bears Say

Bulls Say

Low LeverageVery low debt materially reduces refinancing and solvency risk, preserving financial optionality. Over a 2–6 month horizon this supports continued commercial activity, partner negotiations and potential near-term investment without immediate capital markets stress.

Strong Gross MarginA ~61% gross margin indicates attractive unit economics for ColdZyme, providing structural room to fund marketing, distribution and partner margins. Sustained gross margin supports scalability and improves the chance of long-term path to profitability if fixed costs are controlled.

Established Commercial ModelA hybrid go-to-market—direct operations plus licensing/partners—diversifies revenue streams, reduces single-market concentration and leverages local partners' distribution. This durable model can support steady international sales and royalty income over coming months.

Bears Say

Significant Cash BurnMaterial negative operating and free cash flow signals ongoing cash consumption that must be addressed via improved operations or external funding. Over 2–6 months this raises execution and financing risk and could force dilution or cutbacks if not curtailed.

Persistent LossesDeep and persistent negative net margins indicate the company is far from profitable despite revenue and margin characteristics. Continued losses erode equity and limit ability to self-fund growth, making operational improvement or financing essential for durability.

Weak Revenue MomentumFlat trailing revenue suggests limited top-line momentum despite product presence. Without sustained revenue growth, the company cannot leverage high gross margin to cover fixed costs, prolonging losses and increasing reliance on external capital over the medium term.

ENZY FAQ

What was Enzymatica AB’s price range in the past 12 months?

Enzymatica AB lowest stock price was kr1.60 and its highest was kr3.52 in the past 12 months.

What is Enzymatica AB’s market cap?

Enzymatica AB’s market cap is kr604.41M.

When is Enzymatica AB’s upcoming earnings report date?

Enzymatica AB’s upcoming earnings report date is Jul 16, 2026 which is in 77 days.

How were Enzymatica AB’s earnings last quarter?

Enzymatica AB released its earnings results on Apr 23, 2026. The company reported -kr0.055 earnings per share for the quarter, missing the consensus estimate of N/A by -kr0.055.

Is Enzymatica AB overvalued?

According to Wall Street analysts Enzymatica AB’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Enzymatica AB pay dividends?

Enzymatica AB does not currently pay dividends.

What is Enzymatica AB’s EPS estimate?

Enzymatica AB’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Enzymatica AB have?

Enzymatica AB has 242,735,100 shares outstanding.

What happened to Enzymatica AB’s price movement after its last earnings report?

Enzymatica AB reported an EPS of -kr0.055 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 1.075%.

Which hedge fund is a major shareholder of Enzymatica AB?

Currently, no hedge funds are holding shares in SE:ENZY

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Enzymatica AB

Enzymatica AB, a life science company, develops and sells medical devices for infection-related diseases. The company's product includes ColdZyme mouth spray, which prevents common cold and reduces the duration of illness. It also provides enzyme formulations. The company sells mouth spray under the ViruProtect brand in Denmark; STADAProtect brand in Germany; Psysiomer Stop Virus brand in France; and Zerinol Virus Defense brand in Italy. Enzymatica AB was incorporated in 2007 and is headquartered in Lund, Sweden.